Evaxion Biotech has priced a public offering, seeking to raise $10.8 million before expenses, with closing anticipated tomorrow.
Merck & Co’s MSD Global Health Innovation Fund, which became an Evaxion shareholder in December 2023, is participating in the offering alongside healthcare investment funds and members of the company’s board and management.
Evaxion is a clinical-stage company using AI-driven immunology for vaccine development. The Danish firm intends to use the proceeds to advance its clinical pipeline and support ongoing operations.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze